NCT02646657 - An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions

Colitis, Ulcerative

Interventions

DRUG

Vedolizumab 300 mg

Open-label VEDOLIZUMAB 300 mg at week 0,2,6, 14, 22, 30, 38, 46

Trial Locations (20)

Imeldahospital, Bonheiden

ULB Erasme, Brussels

Ziekenhuis Oost-Limburg, Genk

AZ Sint-Lucas, Ghent

UZ Gent, Ghent

AZ Groeninge, Kortrijk

Leuven AcademicHospital, Leuven

CHC Clinique Saint-Joseph, Liège

CHU Liege, Liège

ZNA Jan Palfijn, Merksem

AZ Damiaan, Ostend

AZ Delta- Roeselare, Roeselare

Semmelweis University, Budapest

University of Debrechen, Debrecen

University of Szeged, Szeged

Academic Medical Center, Amsterdam

OLVG, Amsterdam

Ziekenhuis Gelderse Vallei, Ede

Radboud UMC, Nijmegen

Erasmus MC, Rotterdam